Cementless Femoral Stem Brand Performance for Hemiarthroplasty Treatment of Geriatric Hip Fractures

Ishan D. Shah, MD; *Heather A. Prentice, MD; Kanu Okike, MD; Elizabeth W. Paxton, PhD; Ronald Navarro, MD; Christopher D. Grimsrud, MD, PhD*


Purpose: Existing literature supports the use of cemented hemiarthroplasty for treatment of geriatric displaced femoral neck fractures due to a lower aseptic revision risk. Nevertheless, many surgeons utilize a cementless femoral stem for frail geriatric patients because it is associated with shorter operative times, lower cardiovascular risks, and decreased perioperative mortality. We sought to evaluate differences in all-cause revision risk among cementless femoral stem implants used within a US-based health-care system for displaced femoral neck fractures treated with hemiarthroplasty.

Methods: A retrospective cohort study was conducted using data from a US health-care system's hip fracture registry. 5676 patients aged \geq 60 years who underwent cementless hemiarthroplasty treatment of a displaced femoral neck fracture were identified (2009-2021); procedures were performed by 396 surgeons at 35 hospitals. Stems that were used in at least 300 hemiarthroplasty procedures were included as treatment groups; 7 stems were compared including 4 by DePuy Synthes (Corail, Summit, Summit Basic, and Tri-lock) and 3 by Zimmer-Biomet (M/L Taper, Trabecular Metal, and Versys LD/FX). Multivariable Cox proportional hazard regression models were used to evaluate the risk for all-cause revision with adjustment for confounders and surgeon effects. Summit was used as the reference group in all models.

Results: The final sample included 653 Corail, 402 M/L Taper, 1699 Summit, 1590 Summit Basic, 384 Tri-lock, 637 Trabecular Metal, and 311 Versys LD/FX. In adjusted analysis, M/L Taper (hazard ratio [HR] = 1.98, 95% confidence interval [CI] = 1.28-3.06), Summit Basic (HR = 1.87, 95% CI = 1.36-2.58), and Versys LD/FX (HR = 2.08, 95% CI = 1.28-3.36) had higher all-cause revision risks during follow-up when compared to Summit. No differences were observed for Corail (HR = 0.76, 95% CI = 0.45-1.29), Trabecular Metal (HR = 1.32, 95% CI = 0.86-2.02), or Tri-lock (HR = 1.03, 95% CI = 0.59-1.80) compared to Summit.

Conclusion: In a cohort of 5676 cementless hemiarthroplasties, we found differences in allcause revision risks among different femoral stem brands. Caution should be used when considering M/L Taper, Summit Basic, and Versys LD/FX in the treatment of displaced geriatric femoral neck fractures with cementless hemiarthroplasty.

The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical device they wish to use in clinical practice.



See the meeting website for complete listing of authors' disclosure information. Schedule and presenters subject to change.